SHSunny C. Huang

Sunny C. Huang

*This is an algorithmically generated author record based on publicly available information.

Sunny C. Huang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Peripheral vaccination-induced brain-resident memory CD8+ T cells durably protect mice against intracranial malignancy

    by Madison R. Mix, Cassie M. Sievers, Mariah Hassert, Shravan Kumar Kannan, Lecia L. Pewe, Sunny C. Huang, Rui He, Cori E. Fain, Mohammad Heidarian, Lisa S. Hancox, et al.

    Primary and metastatic brain tumors exhibit resistance to immunotherapies that demonstrate efficacy in peripheral cancer settings. While many immunotherapies aim to enhance CD8 + T cell infiltration and functionality in established tumors, identification of neoantigens support emerging immunopreventative tactics against brain cancer. Functionally potent tissue-resident memory CD8 + T cells (T RM ) can be generated in the brain following peripheral infection or vaccination. However, the ability of brain T RM to prevent intracranial malignancy remains unknown. Here, mice were seeded with tumor-specific or bystander brain T RM via peripheral infection prior to depletion of circulating memory T cells (T CIRCM ) and subsequent brain tumor challenge. Tumor-specific brain T RM durably protected mice against intracranial malignancy even in the absence T CIRCM . These brain T RM persisted in tumor-surviving mice and protected against a second antigen-matched challenge. Importantly, a translationally-relevant mRNA-lipid nanoparticle (LNP) vaccine phenocopied peripheral infection-induced outcomes, generating functional brain T RM that controlled tumor growth. Altogether, this work points to the utility of brain T RM in cancer immunoprevention, supporting the development of antitumor mRNA-LNP vaccines to bolster brain immunity.


  • A Minimally Invasive Method for Generating a Syngeneic Orthotopic Mouse Model of Lung Cancer

    by Danielle J. Foster, Sunny C. Huang, Jennifer A. Petsche, Charles C. Searby, Terry G. Beltz, Val C. Sheffield, Calvin S. Carter

    Non-small cell lung cancer (NSCLC) continues to be the number one cause of cancer-related death for both women and men worldwide. More information needs to be gathered to understand the interactions between cancer cells, the immune system, the microenvironment within each tumor, and the host tissue to develop more effective treatment modalities. Reported here is a simple, repeatable method for inducing cancer within the mouse lung, allowing for the monitoring of tumor growth from early to late-stage disease. The surgical procedure involves a small superficial incision in the skin and an injection of cancer cells through the intercostal muscles into the lung. In vivo imaging systems (IVIS) in combination with cells engineered to express luciferase provide a convenient way of evaluating tumor growth and disease progression over the course of a study. This technique is easily transferable across various models of lung cancer and can be used to test the feasibility and efficacy of novel therapeutics in a preclinical model of lung cancer that mimics the natural tumor microenvironment. This broadens the relevance of both efficacy and safety/toxicity studies using standard-of-care treatments, including surgical resection, radiation, and immunotherapies in conjunction with experimental therapeutics.


  • JoVE Video Dataset

    by Danielle J. Foster, Sunny C. Huang, Jennifer A. Petsche, Charles C. Searby, Terry G. Beltz, Val C. Sheffield, Calvin S. Carter

    Non-small cell lung cancer (NSCLC) continues to be the number one cause of cancer-related death for both women and men worldwide. More information needs to be gathered to understand the interactions between cancer cells, the immune system, the microenvironment within each tumor, and the host tissue to develop more effective treatment modalities. Reported here is a simple, repeatable method for inducing cancer within the mouse lung, allowing for the monitoring of tumor growth from early to late-stage disease. The surgical procedure involves a small superficial incision in the skin and an injection of cancer cells through the intercostal muscles into the lung. In vivo imaging systems (IVIS) in combination with cells engineered to express luciferase provide a convenient way of evaluating tumor growth and disease progression over the course of a study. This technique is easily transferable across various models of lung cancer and can be used to test the feasibility and efficacy of novel therapeutics in a preclinical model of lung cancer that mimics the natural tumor microenvironment. This broadens the relevance of both efficacy and safety/toxicity studies using standard-of-care treatments, including surgical resection, radiation, and immunotherapies in conjunction with experimental therapeutics.